MedTech Terms
    The authoritative reference
    All terms

    AI Imaging Software

    Software that analyzes medical images to triage, detect, or quantify disease.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    AI imaging software uses deep learning to detect findings (intracranial hemorrhage, large-vessel occlusion, pulmonary embolism, lung nodules), quantify disease burden (LVO, ejection fraction, breast density), or triage worklists.
    What the regulation says
    AI imaging software, as a type of Medical Device Software (MDSW), is subject to regulatory oversight by bodies like the FDA in the United States and under the EU Medical Device Regulation (MDR). Regulators classify these devices based on their risk to patients, influencing the conformity assessment routes and pre-market submission requirements. For instance, the FDA provides guidance on Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) to clarify expectations for these adaptive systems.

    What this means in practice

    Cleared as SaMD; commercial success depends on hospital workflow integration, PACS connectivity, and dedicated reimbursement (NTAP, Category III CPT). Growing Predetermined Change Control Plan (PCCP) adoption for model updates.

    Examples

    • An AI imaging software cleared to detect intracranial hemorrhage on CT scans must demonstrate its accuracy and reliability through clinical validation studies, aligning with FDA guidance on SaMD.
    • A manufacturer implements a Predetermined Change Control Plan (PCCP) for its AI software that quantifies ejection fraction, allowing for pre-approved updates to the model's training data without requiring a new 510(k).
    • A hospital integrates an AI breast density quantification tool into its PACS system, ensuring compliance with HIPAA for patient data privacy and cybersecurity standards for software integration.
    Common pitfalls
    • •A common pitfall is failing to validate the AI algorithm on diverse, representative datasets, leading to biased performance and inaccurate diagnoses in real-world clinical populations.
    • •Another mistake is neglecting to establish robust post-market surveillance mechanisms to monitor the AI's performance drift and manage updates in a controlled manner.
    • •Some manufacturers underestimate the regulatory burden associated with modifications to AI models, especially when the changes impact the safety or effectiveness of the device.
    • •Assuming that a Predetermined Change Control Plan (PCCP) eliminates all regulatory submissions for AI model updates is incorrect; significant changes still require review.
    • •Not adequately addressing cybersecurity risks, such as data privacy breaches or malicious attacks on the AI model, can lead to patient harm and regulatory non-compliance.

    Frequently asked questions

    The classification of AI imaging software depends on its intended use and the level of risk it poses to patients. This can range from lower risk classifications, requiring less stringent oversight, to higher risk classifications, demanding extensive clinical evidence and regulatory review. For example, the FDA's risk-based framework for SaMD is a key determinant.
    Grouped by theme

    Primary references

    3 sources
    Link health: 3 verified· last checked 2026-06-20
    FDA·1AdvaMed·1MedTech Europe·1
    1. 1
      FDA AI/ML enabled devices list
      Verified
      FDAfda.gov
    2. 2
      AdvaMed - Industry Reports
      Verified
      AdvaMedadvamed.org
    3. 3
      MedTech Europe - Facts & Figures
      Verified
      MedTech Europemedtecheurope.org

    Inline markers like [1] jump to the matching reference above.